Chapter 14 Clinical Disorders of Primary Malfunctioning of the Lymphatic System

Carlo Bellini and Raoul CM Hennekam

Abstract Primary lymphedema is defined as lymphedema caused by dysplasia of the lymph vessels. This complex group of diseases is discussed in detail from a clinical perspective. A review of the epidemiology and classification of lymphedema on the backdrop of its clinical presentation reveals weaknesses of the present classification system, which, however, is the basis for the choice of optimal patient care. Non-syndrome and syndrome types of primary lymphedema are presented in detail and related molecular findings are summarized.

14.1 Introduction

Lymphedema is a chronic, often progressive swelling of subcutaneous tissue due to failure of the lymphatic system to drain fluid from the interstitial spaces, causing fluid accumulation. Clinically a distinction is made between "primary" and "secondary" lymphedema (Rockson and Rivera 2008). Primary lymphedema is defined as lymphedema caused by dysplasia of the lymph vessels. It is usually congenital and genetically determined. It can be either isolated, so without manifestations in other tissues or outside the lymph vessels, or be part of a disorder that shows other signs and/or symptoms as well (syndrome). The distinction between isolated forms of lymphedema and those that are part of a more generalized entity is not strict as it also depends on the detail of the studies in affected individuals to search for other characteristics next to lymphedema. For instance the presence of an additional row of eyelashes (distichiasis) can be easily missed if not specifically searched for. Primary lymphedema usually affects the extremities as a result of abnormal

C. Bellini

Neonatal Intensive Care Unit, Emergency Department, Gaslini Institute, Genoa, Italy

R.CM. Hennekam (🖂)

Department of Pediatrics and Translational Genetics, Academic Medical Center, Amsterdam, The Netherlands e-mail: r.c.hennekam@amc.uva.nl

F. Kiefer and S. Schulte-Merker (eds.), *Developmental Aspects of the Lymphatic Vascular System*, Advances in Anatomy, Embryology and Cell Biology 214, DOI 10.1007/978-3-7091-1646-3_14, © Springer-Verlag Wien 2014

regional lymph drainage, although visceral drainage showing in lymphangiectasias of for instance gut or lung can also be impaired. Secondary lymphedema is acquired, typically as consequence of an infection, trauma, or malignancy, and will not be discussed any further in this chapter.

Primary lymphedema in children can cause considerable diagnostic difficulties to clinicians and distress to parents. It is essential to obtain a rapid diagnosis and to implement correct treatment at the earliest opportunity. It is estimated that many physicians and surgeons will see less than ten cases of lymphedema in a year (Tiwari et al. 2006). It is therefore imperative that patients are referred at an early stage to a clinic with wide experience and expertise in diagnostics and treatment. Primary lymphedema can also show in lymphangiectasia of internal organs. When affecting the intestines it produces a protein-losing enteropathy and severe malabsorption of lipids and other nutrients (Braamskamp et al. 2010) Congenital pulmonary lymphangiectasia is a rare developmental disorder involving the lung and characterized by pulmonary subpleural, interlobar, perivascular, and peribronchial lymphatic dilatation, complicated by chylous pleural effusion (Bellini et al. 2006). Lymphangiectasias can also occur in other internal organs such as the pericardium, kidneys, and thyroid gland (Van Balkom et al. 2002). Lymphedema should be discerned from lipedema. This is a poorly understood condition characterized by swelling and enlargement of the lower limbs due to abnormal deposition of subcutaneous fat. Lymphatic system involvement seems likely but is actually debated (Child et al. 2010).

The increased knowledge regarding the etiology and pathogenesis of inherited disorders involving the lymphatic system has offered further insight in lymph vessel formation in general. Developments in lymphatic biology and various pathways and mechanisms through which the lymphatic system contributes to the pathogenesis of disorders have been reviewed elsewhere extensively (Tammela and Alitalo 2010; Alitalo 2011; Martinez-Corral and Makinen 2013) and are out of the scope of the present chapter.

14.2 Epidemiology

According to World Health Organization, lymphedema has a worldwide incidence of 300 million cases (~1 in every 20 individuals). Almost half of lymphedemas are of primary origin, due to congenital lymphatic dysplasia and subsequent poor functioning of lymph nodes and/or lymphatic vessels. Some 70 million are of parasitic origin (especially Filaria Bancrofti); 50 million are postsurgery cases, often following breast cancer surgery. The remaining 30 million cases are likely caused by functional problems related to water overload on lymphatic circulation (http://www.chirurgiadeilinfatici.it/en/lymphatic-diseases/lymphedema/epidemiology). The exact prevalence of primary lymphedema is unknown. Within the USA, it has been estimated to be 1.15 per 100,000 children (Smeltzer et al. 1985). A population prevalence of 1.33 per 1,000 for all ages has been reported, but it is probably an

underestimation of the true burden of disease (Moffatt et al. 2003). A female preponderance (M:F = 1:3) is documented, although in part this may represent ascertainment bias.

14.3 Classifications

Primary lymphedema is chronic edema, in which fluid accumulates due to abnormal structure or functions of the lymphatic system (Mortimer 1995). In most cases, edema will be present from birth, but in some cases the lymphedema develops at a later age despite the lymphatic dysplasia being present congenitally. Possibly an increased need of lymphatic functioning due to increased body size and weight or other factors such as hormones or external influences plays a role. Primary isolated lymphatic dysplasias constitute a spectrum of disorders that may manifest by a variety clinical presentations: lymphedema, chylous of effusions, lymphangiomatous malformations with cystic masses and localized gigantism, intestinal lymphangiectasia with malabsorption, lung lymphangiectasia, and lymphangiectasias of other internal organs and glands. Clinical classification of the various types of primary isolated lymphedema has historically been into three groups: lymphedema congenita, lymphedema praecox, and lymphedema tarda. Such classification based purely on the age of onset of the lymphedema does not take into account many other aspects of lymphedema and hinders a refined, detailed classification of phenotypes.

Anomalies of the lymphatic system should be considered as part of vascular anomalies. Mulliken and Glowacki (1982) proposed a classification system for vascular anomalies based on the clinical manifestations and endothelial cell characteristics into two main groups, i.e., hemangiomas and vascular malformations. This classification was adopted by the International Society for the Study of Vascular Anomalies (ISSVA) and with some subsequent modifications widely accepted. At present the two main types of vascular anomalies are vascular tumors (the most common type being hemangioma) and vascular malformations (Enjolras and Mulliken 1997) (Table 14.1). The term malformation that is used in this and other publications to indicate this is mostly wrong as the anomalies are in fact no malformations but dysplasias, although exceptions exist (Hennekam et al. 2013). However, to avoid confusion, we have chosen to use here the terminology used by the ISSVA and will discuss the right terminology with the ISSVA. Vascular malformations include slow-flow malformations which contain the lymphatic malformations (LM). The ISSVA uses a similar classification, splitting the congenital lymphatic dysplasias in truncular (T) or extratruncular (ET), depending on endothelial cells characteristics and the embryonic stage at which the defect was produced. The ET-LMs are embryonic remnants, which have occurred during early stages of vasculogenesis. The immature mesenchymal tissue (in fact dysplastic tissue), of which these malformations are formed, maintains a proliferative capacity. In the case stimuli occur such as pregnancy, hormonal stimulation, trauma, or

Table 14.1 Main characteristics of primary isolated lymphatic malfunctioning

Slow-flow malformations
Divided into truncular or extratruncular lesions
Extratruncular lesions are cystic and divided into microcystic, macrocystic, and mixed type
Extratruncular lesions maintain a proliferative capacity
Fruncular lesions are linked to primary lymphedema, lymphangiectasia, and lymphangiomatosis
Fruncular lesions have no proliferative capacity but behave as malformations
Extratruncular and truncular lesions may coexist within a single patient

surgery, ET-LMs can be stimulated and develop into (micro- and/or macro-) cystic lesions: lymphangioma. The T-LMs develop later during embryogenesis. The vascular tissue is mature and no longer has proliferative capacity. Primary lymphedema is linked with such malformations (Lee et al. 2005).

The Hamburg classification (7th international ISSVA workshop on vascular anomalies, Hamburg, 1988) distinguishes congenital vascular malformations (CVMs) in truncular (T) and extratruncular (ET) forms (Belov 1993; Lee et al. 2005). The Hamburg classification includes a further group of mixed venous malformations (VMs), identified as hemolymphatic malformation (HLM), making the classification of lymphatic malformations (LM) difficult and confusing. The majority of LM lesion exists as an "independent" form of the CVM, either as primary lymphedema representing "truncular" LM lesion or as cystic, cavernous, or capillary lymphangioma representing "extratruncular" LM lesion. Extratruncular LM lesion and truncular LM lesion co-occur together infrequently. In our opinion the Hamburg classification causes considerable problems. It is often extremely difficult to determine whether a finding is truncular or extratruncular as in fact this asks for detailed embryological studies in animal models and in fact also in humans, and the subdivision as is made now is build only for a small part on solid embryological grounds. The various terms used in the classification are often not sufficiently carefully chosen as malformations and dysplasias are insufficiently discerned from one another while this distinction has significant consequences in patient care. Lastly, the subdivision of the various forms of lymphatic malfunctioning is in our opinion not helpful in diagnostics or in providing optimal care to patients, and these issues should be the main determinants in any classification of disorders. A new classification of lymphatic malfunctioning is urgently needed.

Clinically, lymph reflux (backflow of lymph) may occur localized or at systemic level. The backflow of chyle from intestine is characteristic of intestinal lymphangiectasia. Intestinal lymphangiectasia results in protein-losing gastroenteropathy, but it can also affect the abdominal lymphatics or the thoracic duct; if the latter occurs, a chylothorax may develop. The primitive backflow at the level of pleural and pulmonary lymphatics results in pulmonary lymphangiectasia. Lymphangiectasia presents as dilated lymphatics and is usually associated with lymphedema. The pressure in the dilated lymphatics is increased, causing leakage of lymph into surrounding tissues. Lymphangiomatosis is characterized by well-differentiated lymphatic capillaries which are dilated forming cysts and are not always associated with lymphedema. This collection of dilated lymphatics is typically isolated from the remainder of the lymphatic system, which can be completely normal. These are thought to arise from inappropriate connection of the embryonic lymph sacs with the lymphatic system during embryogenesis. The lymphangioma may be uni- or multilocular and macro- or microcystic and may occur in any part of the body. The most common site is the neck (cystic hygroma). Lymphangiomatosis is the widespread, multifocal occurrence of lymphangioma, which can grow aggressively. Lymphangiomatosis can be difficult to diagnose.

In general, LM may coexist with a wide spectrum of CVM and thus be part of complex disorders, affecting the entire circulation system: arteries, veins, lymphatics, and capillaries. This occurrence can be demonstrated in Klippel-Trenaunay syndrome, in which LM may coexist with venous and capillary malformation, or in Parkes Weber syndrome, in which LM presents in association with AV malformation. Indeed, in the entity that goes along with the most widespread lymphatic dysplasia, Hennekam syndrome, the co-occurrence of anomalies of other parts of the vascular system has been described (Van Balkom et al. 2002; Alders et al. 2013). Table 14.1 summarizes the main characteristics of the LMs.

14.4 Isolated Types

Primary congenital lymphedema (Milroy syndrome) is an autosomal dominant disorder of the peripheral lymphatics characterized by lower limb lymphedema, typically affecting the dorsum of the feet. It is usually bilateral and present at birth or evident soon thereafter. Milroy syndrome can also present as lymphedema of the upper limbs, or in markedly affected individuals, the lymphedema can start at the lower limbs and become present at the upper limbs later in life. In such individuals also the external genitalia may become affected, and the differentiation with more marked lymphedema as can be present in Hennekam syndrome may be difficult. Indeed molecularly proven cases with chylothorax and hydrops fetalis have been described (Daniel-Spiegel et al. 2005). Usually the lymphedema in Milroy syndrome becomes gradually more marked during life although rarely it can improve during life as well. The severity of lymphedema shows a marked variability, also intrafamilial, and careful evaluation of family members is regularly needed to establish whom in the family is affected or not. Milroy syndrome can be caused by *WEGFC* mutations.

Primary lymphedema at an older age (Meige syndrome) is an autosomal dominant disorder characterized by peripheral lymphedema predominantly in the lower limbs with onset around puberty. It is thought that the lymphatic system normally functions at ~10 % capacity (Connell et al. 2009). It is assumed to be caused by underdevelopment of the lymphatic vessels, which is however still sufficient in the first years of life but becomes functionally insufficient with increased body size and due to other such as puberty. Upper limb and facial involvement can also present. The lymphedema, which occurs in Meige syndrome, is clinically indistinguishable from that found in the lymphedema-distichiasis syndrome. Indeed there have been publications reporting on *FOXC2* mutations in Meige syndrome, but likely this was a family with lymphedema-distichiasis syndrome. Until now no causative gene for Meige syndrome has been reported. It should be noted there is also an adult-onset segmental dystonia that is termed Meige syndrome (OMIM #128100).

Primary intestinal lymphangiectasia (Vignes and Bellanger 2008) is a disorder with unknown prevalence but which seems to occur only infrequently. It is characterized by hypoproteinemia, edema, and lymphocytopenia, resulting from loss of lymph fluid into the gastrointestinal tract due to intestinal lymphatic vessels dilatation, thus resulting in protein-losing gastro-enteropathy. The loss of lymph fluid can be confirmed by the elevated 24-h clearance of alpha-1-antitrypsin in stools. Bilateral lower limb edema and diarrhea are typical clinical signs that are secondary to the gastro-enteropathy. Lymphocytopenia, hypogammaglobulinemia, hypocalcemia, trace metal deficiency due to malabsorption, and chylous pleural effusions and chylous ascites may occur as secondary consequences in long-standing lymphangiectasia. Primary limb lymphedema may be present as well which can be difficult to distinguish from edema. If this occurs, more generalized lymphatic dysplasia such as occurs in Hennekam syndrome must be considered.

Primary pulmonary lymphangiectasia (Bellini et al. 2006) is an infrequently described developmental disorder involving the lung and characterized by pulmonary subpleural, interlobar, perivascular, and peribronchial lymphatic dilatation. The prevalence is unknown. Pulmonary lymphangiectasias typically present at birth with severe respiratory distress, tachypnea, and cyanosis, with a very high mortality rate at birth or within a few hours of birth. Most reported cases are sporadic and the etiology remains unexplained. Patients affected by PL who survive infancy present medical problems which are characteristic of chronic lung disease. Pulmonary lymphangiectasias also develop at a later age (often puberty of adolescence) in more generalized lymphatic dysplasias such as Hennekam syndrome. Also in such individuals the course is typically unpredictable but eventually fatal.

Chylothorax is defined as an accumulation of chyle in the pleural space. Chylothorax should be considered as a common endpoint for a variety of pathological processes including intrinsic abnormalities of the lymphatic system or disruption of the thoracic duct via trauma, surgery, malignancy, or cardiovascular disease. Congenital defects of the thoracic duct, either isolated or associated with generalized lymphatic vessel dysplasia, are the most frequent cause of congenital chylothorax. Congenital chylothorax is a rare cause of respiratory distress in the newborn but is the most common form of pleural effusion in the neonatal period. Reported incidence ranges from 1:1,000 to 1:15,000 pregnancies (Dubin et al. 2000). The actual incidence in man is probably higher, as intrauterine fetal death as well as stillbirth might well be underestimated. Although familial occurrence has been reported the exact pattern inheritance is not yet known. There is a 2:1 male to female predominance. Both X-linked and autosomal recessive inheritance have been suggested (Straats et al. 1980) and in our opinion it is likely genetically heterogeneous. It has been suggested that congenital pulmonary

lymphangiectasia is a constant pathological finding in congenital chylothorax and that this may imply a common pathogenesis for these disorders (Bellini et al., 2006; Bellini et al., in press).

The course of congenital chylothorax varies widely and the prognosis is unpredictable. Overall mortality for congenital chylothorax has been reported as high as 50 %. The presence of hydrops fetalis has significant prognostic implications (Dubin et al. 2000). In cases of chylothorax complicated by hydrops fetalis, a decrease in survival from 100 to 52 % has been reported. Still, nonimmune hydrops caused by chylothorax carries a better prognosis than nonimmune hydrops in general. The frequency of spontaneous resolution, which may occur either before or after birth, is still unknown. Lymphangiomatosis and lymphangiectasia are the two main anomalies of lymphatic development that cause chylothorax (Fox et al. 1998).

14.5 Syndrome Types

We performed a literature search to obtain an overview of syndromic forms of primary lymphatic malfunctioning. We used the online edition of Mendelian Inheritance in Man and the Winter-Baraitser Dysmorphology Database (WBDD), using as search terms lymphedema, lymphangiectasia, and chylothorax. OMIM is the comprehensive compendium of human genes and genetically determined phenotypes. OMIM contains information on all known Mendelian disorders and over 12,000 genes (http://www.ncbi.nlm.nih.gov/omim). The Winter–Baraitser Dysmorphology Database currently contains information on ~6,000 entities characterized by one or more morphologic abnormalities. It includes Mendelian disorders, chromosomal imbalances, sporadic conditions, and those caused by environmental agents (http://www.lmdatabases.com/).

The thus retrieved entries are summarized in Table 14.2, which contains the main characteristics of each entity such as chromosomal locus, gene involved, pattern of inheritance, and major clinical manifestations. It is impossible to discuss each entity listed in detail. Therefore we will only provide short descriptions of three entities that we consider paradigmatic of the various form of lymphatic maldevelopment.

Lymphedema-distichiasis syndrome is a single gene disorder caused by FOXC2 (forkhead transcription factor) mutations (Sutkowska et al. 2012). Distichiasis (from Greek "distikhos," meaning two rows) is a congenital anomalous growth of eyelashes from the meibomian glands of the eyelid, causing the presence of a double row of eyelashes. It has been suggested that the lymphatic vessel malfunction may be linked to lymphatic valvular insufficiency which causes marked lymphatic reflux (Brice et al. 2002). The severity of lymphedema varies among families and among affected individuals of a single family and is linked to the grade of lymph reflux. "Yellow nail syndrome" has been published as a separate entity characterized by lymphedema and yellow, dystrophic, thick, and slowly growing

Table 14.2 Main characteristics of J	primary lympha	ttic malfunction	oning as pa	urt of a syndr	ome		
	Pattern of				OMIM	Orphanet	
Syndrome	inheritance	Prevalence	Location	Gene	number	identifier	Clinical synopsis
Aagenaes (recurrent cholestasis, lymphedema)	AR AD	Rare	15q	ż	214,900	ORPHA1414	Chronic lymphedema, recurrent neo- natal cholestasis
Al-Gazali-Bakalinova (macrocephaly, multiple epiph- yseal dysplasia)	AR	Rare	15q26.1	KIF7	607,131	ORPHA166024	Macrocephaly, multiple epiphyseal dysplasia, unusual face, lymph- edema distal limbs
Amor (Adams-Oliver-like)	AR	Rare	19p13	DOCK6	614,219	ORPHA974	Intellectual disability, transverse limb anomalies, aplasia cutis scalp, cortical dysplasia, limb lymphedema
Avasthey (pulmonary hypertension, cranial arteriovenous malformations, lymphedema)	AD	Rare	ć	ż	152,900	OPHA86914	Cranial av malformations, pulmonary hypertension, childhood distal limb lymphedema
Bronspiegel (aplasia cutis congenita, intestinal lymphangiectasia)	AR	Rare	ć	ż	207,731	ORPHA1116	Aplasia cutis scalp, coloboma optic disk, heterotopia, intestinal lymphangiectasia
Cantu (hypertrichosis, osteodysplasia, cardiomyopathy)	AD	Unknown	12p12	ABCC9	239,850	ORPHA1517	Hypertrichosis, mildly coarse face, wide ribs, flat vertebrae, pericar- dial effusion, cardiomyopathy, limb lymphedema in adulthood
Cerebellar hypoplasia, lissencephaly, lymphedema	AR	Rare	7q22	RELN	257,320	ORPHA89844	Lissencephaly, seizures, hypotonia, ataxia, small cerebellum, limb lymphedema
Choanal atresia-lymphedema	AR	Rare	1q41	PTPN14	613,611	I	Choanal atresia, small nipples, child- hood limb lymphedema

(continued)							
Myerouyspiasia, reukenna, deamess, lymphedema of lower limbs/geni- talia in infancy-puberty	URFHA2220	014,000	UALAZ	c.12pc	Rare	AD	Emerger (myerodysprasia, lymphedema)
immunodeficiency, osteopetrosis, congenital lymphedema					males		ciency (OLEDAID)
Sparse hair, oligodontia, dry skin, immunodeficiency, octeometrosis	ORPHA98813	300,301	IKBKG	Xq28	1:250,000 males	XL	Ectodermal dysplasia, immune deficiency (OI FDAID)
puberty							
Double row of eyelashes, ptosis, cleft palate. limb lymphedema in	ORPHA33001	153,400	FOXC2	16q24.1	Unknown	AD	Distichiasis-lymphedema
hypertelorism, congenital limb lymphedema							lymphedema)
plasia, broad forehead,							sia, neuronal migration defect,
Intellectual disability, cortical dys-	ORPHA250	136,760	ż	ż	Rare	ż	Da Silva Lopes (frontonasal dyspla-
lephalangy, congenital limb							
telecanthi, nephropathy, brachyte-							lymphedema)
Hypoparathyroidism, ptosis,	ORPHA1563	247,410	i	i	Rare	AR/XL?	Dahlberg (hypoparathyroidism,
pulmonary lymphangiectasia							
papillomata, cardiomyopathy,				•			
curly hair, coarse face, nasal			KRAS	12p12.1			
Intellectual disability, short stature,	ORPHA3071	218,040	HRAS	11p15.5	Unknown	AD	Costello
brachydactyly, limb lymphedema							
broad nose, fractures,							
Intellectual disability, sparse hair,	I	I	ż	8q24	Rare	Chromosomal	Chromosome 8q24 deletion
nary lymphangiectasia							
zures, small callosal body, pulmo-							
Intellectual disability, autism, sei-	I	I	ż	6q27	Rare	Chromosomal	Chromosome 6q27 deletion
loose skin neck, lymphedema							
macrocephaly, hypertelorism,							
Intellectual disability, obesity,	I	I	ż	5p13	Rare	Chromosomal	Chromosome 5p13 duplication

Table 14.2 (continued)							
	Pattern of			1	OMIM	Orphanet	
Syndrome	inheritance	Prevalence	Location	Gene	number	identifier	Clinical synopsis
German (hypotonia, arthrogryposis, unusual face, lymphedema)	AR	Rare	i	i	231,080	ORPHA2077	Hypotonia, arthrogryposis, metopic ridge, cleft palate, hand
Gilewski (unusual face, eventration diaphragm, pulmonary lymphangiectasia)	¢.	Rare	د.	ć	I	I	tympnetenna Broad nasal bridge, small nose, small mouth, eventration diaphragm, small penis, pulmonary
Hennekam (intestinal	AR	Unknown	18q21.32	CCBE1	235,510	ORPHA2136	lymphangiectasia Intellectual disability, flat face,
lymphangiectasia, lymphedema, intellectual disability)							hypertelorism, flat nasal bridge, glaucoma, intestinal lymphangiectasia, congenital severe lymphedema of limbs, genitalia and face
Hennekam (epidermal nevus, arte- riovenous malformations, intes- tinal lymphangiectasia)	د.	Rare	ć	\$	I	I	Epidermal nevus, lipoma, intramedullary hemangioma, intestinal lymphangiectasia
Hypotrichosis, lymphedema, telangiectasia	AR	Rare	20q13.33	SOX18	607,823	ORPHA69735	Progressive hypotrichosis, telangiec- tasia, childhood-pubertal lower limb lymphedema
Irons-Bianchi (congenital heart anomaly, unusual face, lymphedema)	AR	Rare	ć	¢.	601,927	ORPHA86915	Congenital heart defects, prominent forehead, flat nasal bridge, con- genital limb lymphedema
Jacken (CDGIa)	AR	1/20,000	16p13.3	PMM2	212,065	ORPHA79318	Intellectual disability, small cerebel- lum, retinitis pigmentosa, abnor- mal fat pads, stroke-like episodes cardiomyopathy, congenital limb lymbhedema

196

(continued)							
		227100		6q16.2			
туприечения		613,480 601528	VEGEC	1q42.13 4n34 3			
Congenital limb/genitalia	ORPHA79452	153,100	FLT4	5q35.3	Unknown	AD	Milroy
chorioretinal pigmentation, con- genital distal limb lymphedema							sıa, lymphedema
Intellectual disability, microcephaly,	ORPHA2526	152,950	KIF11	10q23.33	Rare	AD	Microcephaly, chorioretinal dyspla-
lymphedema							
liver and spleen, congenital							
scalp, microcephaly, enlarged							lymphedema
Intellectual disability, cutis gyrate	I	Ι	ż	ż	Rare	AR	Microcephaly, cutis verticis gyrata,
malformations, limb lymphedema							
phalanges, multiple capillary							
cortical dysplasia, small distal				i I			malformation
Intellectual disability microcenhaly	ORPHA794016	614 261	STAMBP	2n13	Unknown	AR	Microcenhalv-canillary
Pubertal lymphedema in lower limbs	ORPHA90186	153,200	ż	ż	Unknown	AD	Meige
genital limb lymphedema							
polydactyly hands and feet, con-							4
small ears, deafness, postaxial							dactyly, lymphedema
Underdeveloped malae, small nose,	I	I	ż	ż	Rare	ż	Mandibulofacial dysostosis, poly-
limb lymphedema							
agenesis, congenital resolving							callosum
Intellectual disability, callosal body	I	613,623	ż	ż	Rare	AR	Lymphedema, agenesis corpus
limb lymphedema							
Fat legs, orthostatic edema, lower	ORPHA77243	614,103	ż	ż	Unknown	AD	Lipedema
childhood-adulthood lymphedema							
lymphangioma, asymmetry,							
nous malformations,							,
Cutaneous hemangioma, arteriove-	ORPHA90308	149,000	ż	ż	1/25,000	AD	Klippel-Trenaunay

Table 14.2 (continued)							
	Pattern of				OMIM	Orphanet	
Syndrome	inheritance	Prevalence	Location	Gene	number	identifier	Clinical synopsis
Njolstad (pulmonary lymphangiectasia, lymphedema)	AR	Rare	ζ.	ć	265,300	ORPHA2414	Flat face, hypertelorism, flat nasal bridge, glaucoma, congenital pul- monary lymphangiectasia, congenital lymphedema
Noonan	AD	1/2,500	12q24.13	PTPN11 KPAS	163,950	ОКРНА648 Оррна08733	Short stature, unusual face, webbed neck milmonic stenosis nectus
			2p22.1	SOS1	610,733		carinatum, intestinal
			3p25.2	RAF1	611,552		lymphangiectasia, limb
			1p13.2	NRAS	613,224		lymphedema
			7q34	BRAF	613,706		
			1q22	RIT1	615,355		
Opitz Frias	XL	Rare	Xp22.2	MID1	145,410	ORPHA2745	Intellectual
	Chromosomal		22q11.2	deletion			disability, hypertelorism, cleft
							palate, laryngeal cleft, hypospa-
							dias, pulmonary lymphangiectasia
PTEN hamartoma tumor	AD	1/200,000	10q23.31	PTEN	153,480	ORPHA109	Macrocephaly, hemangioma, lipoma,
							tumors, pulmonary
							lymphangiectasia
Pulmonary stenosis, lymphedema	XL	Rare	Xp11	ż	I	I	Peripheral pulmonary stenosis, distal
							limb lymphedema
Prolidase deficiency	AR	Rare	19q13.11	PEPD	170,100	ORPHA742	Intellectual disability, short stature,
							photosensitivity, recurrent limb
							ulcers, childhood lymphedema
Schindler disease (alpha-N-	AR	Rare	22q13.2	NAGA	104,170	I	Intellectual disability, cortical blind-
acetylgalactosaminidase							ness, deafness, seizures, limb
deficiency)							lymphedema

198

Silver (acro-osteolysis, intestinal lymphangiectasia)	ć	Rare	ć	ż	I	I	Clubbing, acro-osteolysis, bowed radius and ulna, intestinal
Stoll (brachydactyly, tachycardia, lymphedema)	AD	Rare	ć	ż	I	I	Brachydactyly, syndactyly paroxys- mal tachycardia, pubertal limb lymphedema
Tuberous sclerosis	AD	1/10,000	9q34.13 16p13.3	TSC1 TSC2	191,100 613,254	ORPHA805	Depigmented skin lesions, angiofibroma, hamartoma in heart/
							kıdneys/lung/braın, congenital lymphedema
Turner	Chromosomal	1/1,000	X	ć	I	ORPHA881	Short stature, ovarian failure, variable visceral manifestations, congenital limb and sometimes facial
							lymphedema
Urioste	AR	Rare	ć	ć	235,255	ORPHA1655	Oligodactyly, polydactyly, vertebral anomalies, aplasia of internal organs, congenital intestinal lymphoneioraeia
Yellow nail	AD	Unknown	16q24.1	FOXC2	153,300	ORPHA662	Yellow nails, chylothorax, congenital adulthood limb lymphedema
Zellweger	AR	1/25,000– 50,000	7q21.2	PEX1	214,100	ORPHA912	Intellectual disability, hypotonia, sei- zures, unusual face, enlarged liver, intestinal lymphangiectasia
AD autosomal dominant, AR autoson	mal recessive, XI	L X-linked re	cessive, ?	not known			

nails. However, it has become likely that the thickening and yellow discoloration of the nails is not a distinctive sign and can occur in several marked forms of distal limb lymphedema, and most patients with "yellow nail syndrome" may in fact have had lymphedema-distichiasis syndrome (Rezaie et al. 2008).

Hennekam syndrome is a form of very marked lymphatic dysplasia, in which lymph vessels in all body areas are affected (Van Balkom et al. 2002; Alders et al. 2013) and which is caused by mutation in *CCBE1* (Alders et al. 2009). These are also already affected prenatally, and the facial manifestations are thought to be explainable this way. According to the original description (Hennekam et al. 1989) the main characteristics are lymphedema, intestinal lymphangiectasia, intellectual disability (which can be markedly different, also within a single sibship, varying from moderate to severe intellectual disability to completely normal development), and facial signs. The lymphedema has always been congenital, sometimes markedly asymmetric, and after initial decrease in the first years of life has become often gradually progressive with age. Lymphangiectasias are not limited to the intestines but can also be found in the lungs, pleura, pericardium, thyroid gland, and kidneys.

Noonan syndrome is a well-known and frequent entity that is mainly characterized by short stature, unusual face, webbing of the neck, a combined pectus carinatum and excavatum, pulmonic stenosis and later on an increased chance to develop a cardiomyopathy, and a host of further major and minor anomalies. Congenital lymphedema of the distal upper and lower limbs is often but not always present. Some infants and children develop more marked lymphatic malfunctioning including intestinal lymphangiectasias and chylothorax. Within families the variability of the lymphatic system involvement can vary very widely. Indeed even newborns with fatal hydrops have been born to an affected parent with only limited manifestations of the syndrome. Noonan syndrome can be caused by a series of genes that all act in the same MAPK pathway and is one of the entities that form the rasopathies (Rauen 2013).

14.6 Molecular Findings

In isolated and syndromic primary lymphedema various patterns of inheritance can be recognized. The etiology and pathogenesis of the group of disorders is only partially understood (Table 14.2), but research in this field has improved significantly in recent years due to advances in sequencing techniques. Mutations in *VEGFR3*, *FOXC2*, and *SOX18* are known to cause Milroy disease, lymphedemadistichiasis syndrome, and hypotrichosis-telangiectasia-lymphedema syndrome, respectively (Ferrell et al. 1998; Fang et al. 2000; Irrthum et al. 2003; Brice et al. 2005) and *VEGFC* mutations have been found in a Milroy-like disorder (Gordon et al. 2013). *CCBE1* has been reported to be mutated in a proportion of patients with Hennekam syndrome and the analysis of this gene should be studied in every patient with a Hennekam syndrome phenotype or otherwise marked lymphatic malfunctioning (Alders et al. 2009, 2013; Connell et al. 2010), irrespective of the cognitive functioning of affected individuals or the presence or absence of other abnormalities. Chromosome imbalances often result in multiple organ defects and the lymphatic system can be part of this as well, although this is not common, except for Turner syndrome. The number of genes known to cause isolated primary lymphatic malfunctioning is still relatively small compared to the number of genes known to cause similar vascular malfunctioning, and we may expect several other genes to be recognized as being involved in lymphangiogenesis or lymphatic functioning. Indeed sequencing of a series of biologically plausible candidate genes such as *PROX1*, *EMILLIN1*, *LCP2*, *LYVE1*, *NRP2*, *PDPN*, and *SYK* has been suggested as these may be involved in primary lymphedema families.

14.7 Diagnostic Work-Up

The approach to establish the diagnosis in the often complex and sometimes confusing lymphatic disorders can cause difficulties. We suggest a general scheme to provide help in the diagnostic process that can be generally applied in disorders that go along with lymphatic malfunctioning. In all patients a detailed family history of at least two generations and including information to the existence of a possible consanguinity between the parents should be obtained. The examination of a fetus with a suspected lymphatic dysplasia may comprise amniotic fluid examination and chorionic villi study, in particular searching for inherited metabolic disease, lysosomal storage diseases (LSD) included. The examination of a deceased fetus may include autopsy, including babygram, photo-documentation, immuno-histochemical studies, and also a skin biopsy (both for DNA collection and to have access to cultivated cells), samples of other tissues, examination of the placenta, and obtaining and evaluation of fetal urine for metabolic disorders.

Lymphedema in an infant or child is usually diagnosed clinically, but in case of doubt lymphoscintigraphy is the main instrument to establish the diagnosis of lymphedema and to visualize peripheral lymphatic vessels. Lymphoscintigraphy relies on one of the essential functions of the lymphatic system, i.e., to transport lymph. Thus, it can demonstrate each defect in lymphatic functions, as delayed lymphatic drainage, asymmetric or absent visualization of regional lymph nodes, dermal backflow, and interrupted lymphatic structures (Keeley 2006). It can study both superficial and deep lymphatic circulation. Lymphoscintigraphy has been demonstrated to be safe and effective in newborns and in children (Bellini et al. 2008). The diagnostic approach in an individual with visceral lymphangiectasia is usually complex. Lymphoscintigraphy may be helpful and is often combined with computerized tomography scanning and interstitial magnetic resonance imaging. These combined methods of studying lymphatic anomalies are nor widely available however. Additional laboratory exams are usually indicated if lymphangiectasias are present. Determining fecal excretion of alpha-1-antitrypsin helps in diagnosing a protein-losing syndrome and points to intestinal lymphangiectasias. If visceral

effusions are present, such as chylothorax, chylopericardium, and chylous ascites, the abnormal fluids should be obtained and examined to evaluate the triglyceride level (pointing to lymph if >110 mg/dL [= 1.1 mmol/L]), presence of chylomicrons (Sudan III staining), determining the absolute cell count (pointing to lymph if >1,000 cs/mcL, with a lymphocyte fraction of >75–90 %), and the cholesterol level (abnormal if 60 mg/dL or above) (Bellini et al. 2012).

Recognizing congenital lymphatic disorders and diagnosing reliably lymphatic malfunctioning are still challenging. It still starts with clinical recognition, but likely other tools that are patient-friendly such as molecular genetics and other biomarkers can be developed in the near future.

References

- Alders, M., Hogan, B. M., Gjini, E., Salehi, F., Al-Gazali, L., Hennekam, E. A., et al. (2009). Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. *Nature Genetics*, 41, 1272–1274.
- Alders, M., Mendola, A., Adès, L., Al Gazali, L., Bellini, C., Dallapiccola, B., et al. (2013). Evaluation of clinical manifestations in patients with severe lymphedema with and without CCBE1 mutations. *Molecular Syndromology*, 4(3), 107–113.
- Alitalo, K. (2011). The lymphatic vasculature in disease. Nature Medicine, 17, 1371-1380.
- Bellini, C., Boccardo, F., Bonioli, E., & Campisi, C. (2006). Lymphodynamics in the fetus and newborn. *Lymphology*, *39*, 110–117.
- Bellini, C., Boccardo, F., Campisi, C., Villa, G., Taddei, G., Traggiai, C., et al. (2008). Lymphatic dysplasias in newborns and children: The role of lymphoscintigraphy. J Pediatric, 152, 587–589.
- Bellini, C., Ergaz, Z., Boccardo, F., Bellini, T., Bonioli, E., & Ramenghi, L. A. (2013). Dynamics of pleural fluid effusion and chylothorax in the fetus and newborn: Role of the lymphatic system. *Lymphology*. in press.
- Bellini, C., Ergaz, Z., Radicioni, M., Forner-Cordero, I., Witte, M., Perotti, G., et al. (2012). Congenital fetal and neonatal visceral chylous effusions: Neonatal chylothorax and chylous ascites revisited. A multicenter retrospective study. *Lymphology*, 45, 91–102.
- Belov, S. T. (1993). Anatomopathological classification of congenital vascular defects. Seminars in Vascular Surgery, 6, 219–224.
- Braamskamp, M. J., Dolman, K. M., & Tabbers, M. M. (2010). Clinical practice. Protein-losing enteropathy in children. *European Journal of Pediatrics*, 169, 1179–1185.
- Brice, G., Child, A. H., Evans, A., Bell, R., Mansour, S., Burnand, K., et al. (2005). Milroy disease and the VEGFR-3 mutation phenotype. *Journal of Medical Genetics*, 42, 98–102.
- Brice, G., Mansour, S., Bell, R., Collin, J. R., Child, A. H., Brady, A. F., et al. (2002). Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. *Journal of Medical Genetics*, 39, 478–483.
- Child, A. H., Gordon, K. D., Sharpe, P., Brice, G., Ostergaard, P., Jeffery, S., et al. (2010). Lipedema: An inherited condition. *American Journal of Medical Genetics Part A*, 152A, 970–976.
- Connell, F., Brice, G., Mansour, S., & Mortimer, P. (2009). Presentation of childhood lymphoedema. *Journal of Lymphoedema*, 4, 65–72.
- Connell, F., Kalidas, K., Ostergaard, P., Brice, G., Homfray, T., Roberts, L., et al. (2010). Linkage and sequence analysis indicate that CCBE1 is mutated in recessively inherited generalised lymphatic dysplasia. *Human Genetics*, 127, 231–241.
- Daniel-Spiegel, E., Ghalamkarpour, A., Spiegel, R., Weiner, E., Vikkula, M., Shalev, E., et al. (2005). Hydrops fetalis: An unusual prenatal presentation of hereditary congenital lymphedema. *Prenatal Diagnosis*, 25, 1015–1018.

- Dubin, P. J., King, I. N., & Gallagher, P. G. (2000). Congenital chylothorax. Current Opinion in Pediatrics, 12, 505–509.
- Enjolras, O., & Mulliken, J. B. (1997). Vascular tumors and vascular malformations (new issues). *Advances in Dermatology*, *13*, 375–423.
- Fang, J., Dagenais, S. L., Erickson, R. P., Arlt, M. F., Glynn, M. W., Gorski, J. L., et al. (2000). Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. *American Journal of Human Genetics*, 67, 1382–1388.
- Ferrell, R. E., Levinson, K. L., Esman, J. H., Kimak, M. A., Lawrence, E. C., Barmada, M. M., et al. (1998). Hereditary lymphoedema: Evidence for linkage and genetic heterogeneity. *Human Molecular Genetics*, 7, 2073–2078.
- Fox, G. F., Challis, D., O'Brien, K. K., Kelly, E. N., & Ryan, G. (1998). Congenital chylothorax in siblings. Acta Paediatrica, 87, 1010–1012.
- Gordon, K., Schulte, D., Brice, G., Simpson, M. A., Roukens, M. G., van Impel, A., et al. (2013). Mutation in vascular endothelial growth factor-C, a ligand for vascular endothelial growth factor receptor-3, is associated with autosomal dominant milroy-like primary lymphedema. *Circulation Research*, 112(6), 956–960.
- Hennekam, R. C., Biesecker, L. G., Allanson, J. E., Hall, J. G., Opitz, J. M., Temple, I. K., et al. (2013). Elements of morphology: General terms for congenital anomalies. *American Journal of Medical Genetics*. [epub ahead of print].
- Hennekam, R. C. M., Geerdink, R. A., Hamel, B. C., Hennekam, F. A., Kraus, P., Rammeloo, J. A., et al. (1989). Autosomal recessive intestinal lymphangiectasia and lymphoedema, with facial anomalies and mental retardation. *American Journal of Medical Genetics*, 34, 593–600.
- Irrthum, A., Devriendt, K., Chitayat, D., Matthijs, G., Glade, C., Steijlen, P. M., et al. (2003). Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosislymphedema-telangiectasia. *American Journal of Human Genetics*, 72, 1470–1478.
- Keeley, V. (2006). The use of lymphoscintigraphy in the management of chronic oedema. *Journal* of Lymphoedema, 1, 42–57.
- Lee, B. B., Kim, Y. W., Seo, J. M., Hwang, J. H., Do, Y. S., Kim, D. I., et al. (2005). Current concepts in lymphatic malformation. *Vascular and Endovascular Surgery*, 39, 67–81.
- Martinez-Corral, I., & Makinen, T. (2013). Regulation of lymphatic vascular morphogenesis: Implications for pathological (tumor) lymphangiogenesis. *Experimental Cell Research*, *S0014–4827*(13), 00034–00037. doi:10.1016/j.yexcr.2013.01.016 [Epub ahead of print].
- Moffatt, C. J., Franks, P. J., Doherty, D. C., Williams, A. F., Badger, C., Jeffs, E., et al. (2003). Lymphoedema: An underestimated health problem. *Quarterly Journal of Medicine*, 96, 731–738.
- Mortimer, P. S. (1995). Managing lymphoedema. Clinical and Experimental Dermatology, 20, 98–106.
- Mulliken, J. B., & Glowacki, X. X. (1982). Classification of pediatric vascular lesions. Journal of Plastic and Reconstructive Surgery, 69, 412–422.
- Rauen, K. A. (2013). The RASopathies. Annual Review Genomics Human Genetics, 14, 355–369.
- Rezaie, T., Ghoroghchian, R., Bell, R., Brice, G., Hasan, A., Burnand, K., et al. (2008). Primary non-syndromic lymphoedema (Meige disease) is not caused by mutations in FOXC2. *European Journal of Human Genetics*, 16, 300–304.
- Rockson, S. G., & Rivera, K. K. (2008). Estimating the population burden of lymphoedema. Annals of the New York Academy of Sciences, 1131, 147–154.
- Smeltzer, D. M., Stickler, G. B., & Schirger, A. (1985). Primary lymphedema in children and adolescents: A follow-up study and review. *Pediatrics*, 76, 206–218.
- Straats, B. A., Ellefson, R. D., Budahn, L. L., Dines, D. E., Prakash, U. B., & Offord, K. (1980). The lipoprotein profile of chylous and nonchylous pleural effusions. *Mayo Clinic Proceedings*, 11, 700–704.
- Sutkowska, E., Gil, J., Stembalska, A., Hill-Bator, A., & Szuba, A. (2012). Novel mutation in the FOXC2 gene in three generations of a family with lymphoedema-distichiasis syndrome. *Gene*, 498, 96–99.

- Tammela, T., & Alitalo, K. (2010). Lymphangiogenesis: Molecular mechanisms and future promise. Cell, 140, 460–476.
- Tiwari, A., Myint, F., & Hamilton, G. (2006). Management of lower limb lymphoedema in the United Kingdom. *European Journal of Vascular and Endovascular Surgery*, 31, 311–315.
- Van Balkom, I. D. C., Alders, M., Allanson, J., Bellini, C., Frank, U., De Jong, G., et al. (2002). Lymphoedema-lymphangiectasia-mental retardation (Hennekam) syndrome: A review. American Journal of Medical Genetics, 112, 412–421.
- Vignes, S., & Bellanger, J. (2008). Primary intestinal lymphangiectasia (Waldmann's disease). Orphanet Journal of Rare Diseases, 3, 5.